February 10, 2017 10:04 AM EST
Bioregnum
Opinion

An­oth­er biotech games the sys­tem, and every­one gets to pay for the fall­out

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

The FDA …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Re­searchers make case against Gilead in HIV prod­uct hop­ping fight

Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs

Mallinck­rodt and En­do ex­plor­ing a $7B merg­er — re­port

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times